Emerging Perspectives in Addiction Psychiatry
The Journal of Clinical Psychiatry – August 03, 2023
Source: OpenAlex
Summary
Opioid overdoses claim 130 lives daily, often exacerbated by alcohol dependence. Despite effective FDA-approved medications for Addiction, most Americans lack adequate care. However, new avenues in Medicine and Psychiatry are emerging. Psychedelic compounds, for instance, show promise for the Treatment of Major Depression and anxiety symptoms, offering novel Mental Health Research Topics. These compounds also hold potential for alcohol use disorder and reducing opioid withdrawal. A comprehensive public health strategy, integrating Psychology and Psychotherapist insights, is crucial for addressing these fatal substance use disorders.
Abstract
Despite their legality, alcohol and tobacco both have a well-documented potential for misuse and elevate users' likelihood for disease. Dependence on alcohol also contributes to opioid overdoses, which claim 130 lives every day. Although awareness of the opioid epidemic is rising broadly among health care professionals, a majority of Americans still do not receive adequate, FDA-approved medications for their addiction. Effective medications are available for alcohol use disorder and medications for opioid use disorder have validated benefits that justify their use. In recent years, psychedelic compounds have attracted interest among scientists for their potential to alter mood and cognition in beneficial manners. Already, some evidence supports the use of psilocybin in alleviating symptoms of depression and anxiety; psychedelic compounds also have potential as alcohol use disorder treatments and may help reduce symptoms tied to opioid withdrawal. Because substance use disorders can culminate in death, a comprehensive, integrated, public health approach to the treatment of people with substance use disorders is essential.